What is BPC-157?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a protective protein found in human gastric juice. It was first isolated and characterized by researchers at the University of Zagreb in the early 1990s. Unlike most bioactive peptides, BPC-157 is remarkably stable in gastric acid, a property attributed to its origin in the gastrointestinal tract.
The compound has been studied extensively in preclinical models for its tissue-protective and regenerative properties. Research spans over 100 published studies demonstrating effects on tendon healing, muscle repair, bone fracture recovery, nerve regeneration, and gastrointestinal healing. The peptide's angiogenic properties — promoting new blood vessel formation at injury sites — appear central to its tissue repair mechanism across multiple organ systems.
One of the most clinically relevant findings is BPC-157's ability to counteract NSAID-induced gastrointestinal damage. In animal models, it has reversed lesions caused by ibuprofen, diclofenac, and aspirin. It has also shown protective effects against alcohol-induced gastric damage and inflammatory bowel disease models.
Mechanism of Action
BPC-157's mechanism of action is multifactorial and not fully elucidated, but decades of preclinical research have identified several key pathways:
Nitric Oxide (NO) System
BPC-157 modulates the nitric oxide system, which plays a critical role in vasodilation, blood flow regulation, and tissue repair signaling. Studies demonstrate that BPC-157 can counteract both NO-synthase inhibition (L-NAME) and NO-synthase overstimulation (L-arginine), suggesting it acts as a stabilizer of the NO system rather than simply increasing or decreasing NO production [4].
Growth Factor Upregulation
The peptide upregulates expression of several key growth factors involved in tissue repair, particularly vascular endothelial growth factor (VEGF), epidermal growth factor (EGF), and transforming growth factor beta (TGF-β). This promotes angiogenesis — the formation of new blood vessels at injury sites — which is considered the primary mechanism behind its tissue-healing effects [2].
FAK-Paxillin Pathway
BPC-157 interacts with the focal adhesion kinase (FAK)-paxillin signaling pathway, which is essential for cell migration, adhesion, and spreading. This pathway activation promotes the migration of fibroblasts and endothelial cells to wound sites, accelerating the repair process [3].
Neurotransmitter System Interactions
Research has demonstrated interactions with both the dopaminergic and serotonergic systems. BPC-157 appears to modulate dopamine receptor sensitivity and has shown protective effects against dopamine-depleting agents. It also influences GABAergic transmission and has demonstrated anxiolytic-like effects in behavioral models.
Dosing Protocol
BPC-157 dosing in preclinical research has been remarkably consistent across published studies. The standard approach uses fixed-dose protocols, though weight-based calculations (1–10 mcg/kg) appear in some literature.
| Protocol | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Standard recovery | 250 mcg | Once daily | 4–8 weeks | Most commonly referenced in literature |
| Accelerated recovery | 250 mcg | Twice daily | 4–6 weeks | Split AM/PM dosing |
| High-dose protocol | 500 mcg | Once daily | 4–6 weeks | Used in some soft tissue injury studies |
| Localized injury | 250 mcg | 1–2x daily | 4–8 weeks | SubQ injection proximal to injury site |
| GI protocol | 500 mcg | Once daily | 4–8 weeks | Abdominal subcutaneous injection |
- Inject on an empty stomach or at least 30 minutes before meals for optimal absorption.
- For localized injuries (tendon, muscle, joint), inject subcutaneously as close to the affected area as possible.
- For systemic or GI applications, inject into abdominal subcutaneous tissue.
- No published evidence of tolerance development; however, standard practice is to cycle off periodically.
Reconstitution Guide
Reconstitute lyophilized BPC-157 with bacteriostatic water. The peptide dissolves readily without requiring excessive mixing. Never shake the vial.
- Remove the plastic cap from the BPC-157 vial and wipe the rubber stopper with an alcohol swab. Allow to dry.
- Draw
2 mLof bacteriostatic water into a sterile syringe. For a 5 mg vial, this yields a concentration of2,500 mcg/mL. - Insert the needle through the rubber stopper at a slight angle. Inject the water slowly against the inner wall of the vial — do not spray directly onto the peptide powder.
- Allow the vial to sit for 1–2 minutes. Gently roll the vial between your palms if needed. Do not shake or vortex.
- The solution should be completely clear and colorless. Discard if you observe any cloudiness, particulate matter, or discoloration.
5 mg vial + 2 mL BAC water: Concentration = 2,500 mcg/mL
250 mcg dose = 10 units (0.1 mL) on a 100-unit insulin syringe
500 mcg dose = 20 units (0.2 mL) on a 100-unit insulin syringe
Doses per vial: 20 doses at 250 mcg, or 10 doses at 500 mcg
- 3 vials BPC-157 (5 mg each) — provides 60 doses, covers 56 days with margin
- 3 vials bacteriostatic water (30 mL each)
- 60 insulin syringes (29–31 gauge, 100-unit)
- Alcohol prep pads
Injection Technique
BPC-157 is administered via subcutaneous (SubQ) injection. This is the most common and practical route for peptide self-administration.
- Clean the injection site with an alcohol swab and allow it to air dry completely (approximately 30 seconds). Common sites: lower abdomen (2 inches from the navel), upper thigh, or proximal to the target injury.
- Draw the dose. Insert the needle into the vial through the rubber stopper. Invert the vial and draw the calculated number of units slowly. Tap the syringe to move any air bubbles to the top, then push them out gently.
- Pinch the skin at the injection site to create a fold of subcutaneous tissue. Insert the needle at a 45-degree angle in a quick, smooth motion. Release the skin fold.
- Inject slowly. Depress the plunger steadily over 5–10 seconds. Withdraw the needle at the same angle it was inserted. Apply gentle pressure with a clean swab if needed.
Rotate injection sites to prevent lipodystrophy (localized fat tissue changes). For abdominal injections, use a clock pattern around the navel. For localized injury protocols, alternate between 2–3 sites near the target area. Allow at least 1 inch between injection sites.
Storage & Stability
BPC-157 is notably more stable than many peptides due to its gastric acid resistance, but proper storage practices are essential to maintain potency.
- Keep vials upright and away from direct light.
- If condensation forms on a cold vial, allow it to reach room temperature before opening to prevent moisture contamination.
- Never re-freeze a reconstituted vial. Discard if left at room temperature for more than 4 hours.
- Label reconstituted vials with the date to track the 30-day use window.
Side Effects & Considerations
BPC-157 has demonstrated a remarkably favorable safety profile across numerous preclinical studies. No lethal dose (LD50) has been established, even at concentrations far exceeding standard protocols.
Commonly Reported
- Mild injection site irritation — redness, minor swelling, or itching at the injection point. Usually resolves within 30 minutes.
- Nausea — reported infrequently, more common at higher doses (500 mcg+) or when injecting on a full stomach.
- Lightheadedness or dizziness — reported rarely, typically in the first few days of use.
Theoretical Considerations
- BPC-157 is a potent angiogenic agent. While no evidence of tumor growth promotion exists in published literature, individuals with active malignancies should exercise caution due to the potential for enhanced blood vessel formation near tumors.
- Interactions with blood pressure medications are theoretically possible due to the peptide's effects on the NO system and vascular tone.
- No human clinical trials have been completed as of this writing. All safety data is derived from preclinical animal models.
BPC-157 is classified as a research peptide. It is not FDA-approved for any clinical indication. All information presented here reflects published preclinical research and should not be construed as medical advice or a treatment recommendation.
Stacking Protocols
BPC-157 is frequently studied alongside other peptides in combination protocols. The most well-documented combination is with TB-500 (Thymosin Beta-4 fragment).
BPC-157 + TB-500 (Recovery Stack)
The most common combination in the research community. BPC-157 promotes localized tissue repair and angiogenesis, while TB-500 works systemically to reduce inflammation and promote cell migration. The two peptides are believed to complement each other through non-overlapping mechanisms.
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| BPC-157 | 250 mcg | Once daily (near injury) | 4–8 weeks |
| TB-500 | 2–2.5 mg | Twice weekly (loading) | 4–6 weeks |
| TB-500 (maintenance) | 2 mg | Every 2 weeks | Ongoing |
Lifestyle Factors
Research suggests the following complementary practices may support peptide-mediated recovery:
- Sleep: Growth hormone release peaks during deep sleep. Prioritize 7–9 hours to maximize the body's natural repair window.
- Protein intake: Adequate amino acid availability supports the tissue remodeling that BPC-157 initiates. Aim for 1.2–1.6 g/kg body weight.
- Hydration: Adequate fluid intake supports vascular function and nutrient transport to healing tissues.
- Low-impact movement: Gentle movement increases blood flow to healing areas without reinjury risk. Avoid high-intensity training on the target area during the recovery cycle.
BPC-157 is available in 5 mg vials from Heritage Labs USA, a U.S.-based research peptide supplier with batch-level purity verification.
- Third-party purity testing (HPLC & MS)
- U.S.-based fulfillment
- Published COAs per lot
Literature & Citations
- Sikiric P, Hahm KB, Blagaic AB, et al. Pentadecapeptide BPC 157 and its role in healing: A comprehensive review. Curr Pharm Des. 2018;24(18):2012-2032. PubMed
- Seiwerth S, Brcic L, Vuletic LB, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014;20(7):1014-1025. PubMed
- Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014;20(7):1126-1135. PubMed
- Vukojevic J, Siroglavic M, Kasun M, et al. Rat inferior caval vein (ICV) ligature and BPC 157. Vasc Pharmacol. 2018;106:46-59. PubMed
- Sikiric P, et al. Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Curr Neuropharmacol. 2016;14(8):857-865. PubMed
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. PubMed
- Sebecic B, et al. Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation. Bone. 1999;24(3):195-202. PubMed